<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="603">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>28/09/2005</approvaldate>
  <actrnumber>ACTRN12605000532606</actrnumber>
  <trial_identification>
    <studytitle>How does raloxifene influence the effects of growth hormone replacement</studytitle>
    <scientifictitle>Modulation of growth hormone action during growth hormone replacement in growth hormone-deficient women: comparison of raloxifene and oral oestrogen</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hypopituitary women</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic and endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Raloxifene (60 mg daily) for 6 - 18 months
17 beta oestradiol (2 mg) for 6 - 18 months
recombinant uman growth hormone (Humaloge) (0.5 mg daily) for 24 months</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Short term measurements of biochemical markers of the GH-IGF-axis as well as substrate metabolism and protein turnover</outcome>
      <timepoint>At baseline, after 1 month of growth hormone alone, growth hormone + raloxifene or growth hormone + oestradiol.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Long term effects on body composition measured by DEXA </outcome>
      <timepoint>At baseline, after 6 and 12 and 24 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in bone turnover markers and cardiovascular risk factors are measured: </outcome>
      <timepoint>At baseline, after 1 month of growth hormone alone, growth hormone + raloxifene or growth hormone + oestradiol</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in bone turnover markers and cardiovascular risk factors are measured: </outcome>
      <timepoint>On long term treatment with growth hormone + raloxifene or growth hormone + oestradiol after 6, 12 and 24 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Long term effects on body composition measured by DEXA.</outcome>
      <timepoint>At baseline, after 6 and 12 and 24 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hypopituitarism (deficient in growth hormone and sex steroids).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed envelopes</concealment>
    <sequence>coin toss</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>5/09/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Endocrinology, St Vincents Hospital Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Raloxifene is a member of a family of compounds called selective estrogen receptor modulators (SERMS) that exert many of the beneficial effects of estrogen replacement without the associated increase in risk of breast and uterine cancer. Growth hormone (GH) replacement is beneficial in adults with   hypopituitarism.  Most GH deficient women also require oestrogen replacement.  Oral oestrogens antagonise GH action at the liver, thereby reducing its beneficial effects on body composition and metabolism. The aim of this study is to investigate whether  SERMs exert less of a negative influence on the effects of  GH replacement, and therefore would be  superior to conventional estrogen replacement in this setting.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Garvan Institute of Medical Research</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Udo Meinhardt</name>
      <address>Pituitary Research Unit
Garvan Institute of Medical Research
384 Victoria St
Darlinghurst NSW 2010</address>
      <phone>+61 2 92958486</phone>
      <fax>+61 2 92958411</fax>
      <email>u.meinhardt@garvan.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Ken Ho</name>
      <address>Professor of Medicine
Head
Pituitary Research Unit
Garvan Institute Chairman
Department of Endocrinology
Garvan Institute of Medical Research
St Vincents Hospital
384 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 92958203</phone>
      <fax>+61 2 92958411</fax>
      <email>k.ho@garvan.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>